Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...
A new cohort study included 778 men with prostate cancer who had received either radiation or surgery within 1 year of diagnosis. Patients who lived in rural areas had nearly twice the rate of ...
Rural men had almost twice the risk of prostate cancer biochemical recurrence as urban men in the US. Patients living in rural areas may be at an increased risk for prostate cancer biochemical ...
ROCHESTER, Minn. — To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department ...
Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data. Anatomical location of ...
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...
The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results